‌

Q1 2019 Data Report

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

This quarterly data report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

Back to Publications

Global Landscape

917+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

502North America23Oceania1Africa145Asia15South America233Europe & Israel

Financings

Total Q1 2019 Global Financings

Total Global Financing

$2.2 Billion

 42%

Decrease from Q1 2018

14.3%85.7%01234567891011121314Q1 2019Full Year 2018
Gene & Gene-modified
Cell Therapy

$2.1 Billion

 78%

Decrease from Q1 2018

18.1%81.9%012345678910Q1 2019Full Year 2018
Cell Therapy

$823 Million

 89%

Decrease from Q1 2018

9.9%90.1%0110002000300040005000600070008000Q1 2019Full Year 2018
Tissue Engineering

$14 Million

 98%

Decrease from Q1 2018

98.5%0101002003004005006007008009001000Q1 2019Full Year 2018

Total Global Financings by Type, by Year

1176768898535619274715156329071245254399511211451689IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000m$5,500m$6,000mQ1 2019Full Year 2018Full Year 2017
621894413540Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m$24,000mQ1 2019Full Year 2018Full Year 2017

1,060

Clinical trials underway
worldwide by the end of Q1 2019

PH. 1

349

PH. 2

618

PH. 3

93

32.9%58.3%8.8%050100150200250300350400450500550600650Phase 1Phase 2Phase 3

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q1 2019

Gene Therapy
33.1%58.3%8.6%020406080100120140160180200220Phase IPhase IIPhase III
Gene-Modified
Cell Therapy
42.8%52.7%0020406080100120140160180200Phase IPhase IIPhase III
Cell Therapy
20.5%67.9%11.6%020406080100120140160180Phase IPhase IIPhase III
Tissue Engineering
23.9%47.8%28.3%01011121314151617181920212223Phase IPhase IIPhase III

Clinical Trials by Indication: Q1 2019

Oncology
618
Cardiovascular
67
Central Nervous System
60
Musculoskeletal
56
Endocrine Metabolic & Genetic Disorders
44
Ophthalmology
38
Dermatology
36
Immunology & Inflammation
36
Hematology
35
Infectious Disease
21
Gastroenterology
15
Genitourinary Disorders
14
Respiratory
10
Lymphatic Diseases
3
Surgery
3
Ear Diseases
2
Geriatric Diseases
2

Report Infographics

View Full Report View Past Reports

Alliance for Regenerative Medicine

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium